Published in F1000Res on June 27, 2016
Autoimmune response to acetylcholine receptor. Science (1973) 4.59
The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell (1996) 3.81
Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell (2008) 3.29
Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med (2001) 3.26
LRP4 serves as a coreceptor of agrin. Neuron (2008) 2.98
IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain (2008) 2.91
Anti-agrin autoantibodies in myasthenia gravis. Neurology (2014) 2.65
Neurotransmitter acetylcholine negatively regulates neuromuscular synapse formation by a Cdk5-dependent mechanism. Neuron (2005) 2.46
Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain (1980) 2.36
Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury. Neuron (1995) 2.17
Myasthenia gravis: passive transfer from man to mouse. Science (1975) 1.90
Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol (2004) 1.89
Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology (2011) 1.77
Agrin promotes synaptic differentiation by counteracting an inhibitory effect of neurotransmitter. Proc Natl Acad Sci U S A (2005) 1.75
Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol (2011) 1.69
Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol (2012) 1.67
Neuromuscular disease. DOK7 gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction. Science (2014) 1.55
Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol (2002) 1.54
A genome-wide association study of myasthenia gravis. JAMA Neurol (2015) 1.52
Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol (2011) 1.47
Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol (2011) 1.39
What have we learned from the congenital myasthenic syndromes. J Mol Neurosci (2009) 1.29
Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun (2014) 1.29
Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmun (2014) 1.24
Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol (2008) 1.23
Rapsyn interaction with calpain stabilizes AChR clusters at the neuromuscular junction. Neuron (2007) 1.19
Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08. Ann Neurol (2012) 1.19
Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain (2012) 1.19
Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest (2006) 1.13
The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol (2006) 1.12
The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J Exp Med (1991) 1.12
The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via dimerization. Mol Cell (2010) 1.12
Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Autoimmunity (2010) 1.11
Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol (2006) 1.09
A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun (2013) 1.08
Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest (2013) 1.03
Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice. Exp Neurol (2011) 1.03
Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. Eur J Immunol (1992) 1.03
MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci U S A (2013) 1.02
Muscle specific kinase: organiser of synaptic membrane domains. Int J Biochem Cell Biol (2010) 1.01
Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice. J Physiol (2010) 1.01
Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody. J Physiol (2013) 1.00
MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters. PLoS One (2013) 1.00
Skeletal muscle IP3R1 receptors amplify physiological and pathological synaptic calcium signals. J Neurosci (2011) 0.99
How myasthenia gravis alters the safety factor for neuromuscular transmission. J Neuroimmunol (2008) 0.97
Autoantibodies to agrin in myasthenia gravis patients. PLoS One (2014) 0.97
Caspase-3 cleavage of dishevelled induces elimination of postsynaptic structures. Dev Cell (2014) 0.97
Agrin and synaptic laminin are required to maintain adult neuromuscular junctions. PLoS One (2012) 0.94
Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects. Exp Neurol (2012) 0.93
Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmun Rev (2013) 0.93
Acetylcholine release in myasthenia gravis: regulation at single end-plate level. Ann Neurol (1995) 0.93
Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am J Pathol (2011) 0.92
The search for new antigenic targets in myasthenia gravis. Ann N Y Acad Sci (2012) 0.92
Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors. Exp Neurol (2012) 0.90
MuSK levels differ between adult skeletal muscles and influence postsynaptic plasticity. Eur J Neurosci (2011) 0.90
Increasing MuSK activity delays denervation and improves motor function in ALS mice. Cell Rep (2012) 0.90
Acetylcholine receptor antibody characteristics in myasthenia gravis. Fractionation of alpha-bungarotoxin binding site antibodies and their relationship to IgG subclass. J Neuroimmunol (1983) 0.89
Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev (2013) 0.89
Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes. Arch Neurol (2011) 0.89
Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades? Arch Immunol Ther Exp (Warsz) (2011) 0.87
Antibodies to clustered acetylcholine receptor: expanding the phenotype. Eur J Neurol (2013) 0.85
Thymoma related myasthenia gravis in humans and potential animal models. Exp Neurol (2015) 0.83
Complement associated pathogenic mechanisms in myasthenia gravis. Autoimmun Rev (2013) 0.83
Cell surface complement regulators moderate experimental myasthenia gravis pathology. Muscle Nerve (2012) 0.83
IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis. Eur J Immunol (2015) 0.82
Muscle-specific kinase (MuSK) autoantibodies suppress the MuSK pathway and ACh receptor retention at the mouse neuromuscular junction. J Physiol (2014) 0.81
Myasthenia gravis. Autoimmunity (2004) 0.81
Preferential production of IgG1, IL-4 and IL-10 in MuSK-immunized mice. Clin Immunol (2014) 0.81
Electrophysiological analysis of neuromuscular synaptic function in myasthenia gravis patients and animal models. Exp Neurol (2015) 0.81
Experimental autoimmune myasthenia gravis in the mouse. Curr Protoc Immunol (2013) 0.80
Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis. Exp Neurol (2014) 0.78
Collagen Q and anti-MuSK autoantibody competitively suppress agrin/LRP4/MuSK signaling. Sci Rep (2015) 0.78
Guidelines for pre-clinical assessment of the acetylcholine receptor--specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs. Exp Neurol (2015) 0.77
Altered active zones, vesicle pools, nerve terminal conductivity, and morphology during experimental MuSK myasthenia gravis. PLoS One (2014) 0.77
Forced expression of muscle specific kinase slows postsynaptic acetylcholine receptor loss in a mouse model of MuSK myasthenia gravis. Physiol Rep (2015) 0.76